Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Peanut Allergy Treatment Market

Peanut Allergy Treatment Market Size

Report ID: GMI10199
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Peanut Allergy Treatment Market Size

Peanut Allergy Treatment Market size was valued at USD 483.5 million in 2023 and is anticipated to showcase growth at 12.1% CAGR from 2024 to 2032. Growing prevalence of peanut allergies, increasing approvals for immunotherapeutic treatments, and increasing investments for developing new treatment modalities is driving the revenue growth of the global market. Additionally, rising awareness towards timely treatment of peanut allergies is also adding to the revenue growth of the market.

To get key market trends

Download Free Sample

Peanut allergy treatment includes various therapeutic interventions designed to manage and treat allergies. This market includes a range of treatment modalities aimed at reducing allergic reactions and increase tolerance to peanut proteins to improve the quality of life of patients.

Peanut Allergy Treatment Market Report Attributes
Report Attribute	Details
Base Year:	2023
Peanut Allergy Treatment Market Size in 2023:	USD 483.5 Million
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	12.1%
2032 Value Projection:	USD 1.3 Billion
Historical Data for:	2021 - 2023
No. of Pages:	80
Tables, Charts & Figures:	152
Segments covered:	Route of Administration, Drug Class, Distribution Channel, and Region
Growth Drivers:	Growing prevalence of peanut allergies Increasing approvals for immunotherapeutic treatments Increasing investments for developing new treatment modalities Rising awareness towards timely treatment of peanut allergies
Pitfalls & Challenges:	High cost of immunotherapeutic treatments Safety issues during initial treatment phase

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Peanut allergy treatment industry size was worth USD 483.5 million in 2023 and is projected to expand at 12.1% CAGR from 2024 to 2032, due to growing prevalence of peanut allergies, and increasing investments for developing new treatment modalities.

The injectable route of administration segment in the peanut allergy treatment industry accounted for 51.4% share in 2023 as they find extensive use in delivering epinephrine and immunotherapeutic treatments such as Dupixent.

The epinephrine drug class segment in the peanut allergy treatment industry accounted for USD 233 million in 2023 owing to drug ability to reverse any life-threatening symptoms such as swelling of the airway and low blood pressure.

North America peanut allergy treatment industry accounted for 41.3% share in 2023 and is projected to expand at substantial rate from 2024 to 2032, led by the increasing prevalence of peanut allergies in the region.